Immuneering signs $25M Sanofi placement contingent on public offering; Phase 2a pancreatic data shows 86% OS

Immuneering Corp

Sanofi subsidiary Aventis agrees to purchase $25M in stock at public offering price; closing contingent on $75M+ public offering by Sept 26, 2025.
Updated Phase 2a atebimetinib + mGnP data in 1L pancreatic cancer (N=34): 86% OS at 9 mos (vs ~47% SOC), median PFS 9.6 mos, median OS not reached.
Safety profile: Grade ≥3 TEAEs in ≥10% were anemia (24%) and neutropenia (18%); no Grade 5 events.
Near-term milestones: regulatory feedback on Phase 3 plans in Q4 2025; potential Phase 3 start by end 2025 and first patient by mid-2026.
Leerink Partners and Oppenheimer & Co. act as joint bookrunners for the public offering and placement agents for private placement.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.